PharmaShots’ Post

Bristol Myers Squibb Presents the Long-Term P-III (MAVA-LTE) Trial Data of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) #bms #camzyos #symptomaticobstructivehypertrophiccardiomyopathy #clinicaltrial #phase3 #mavalte

Pharmacogenomics is revolutionizing how we approach treatment. By understanding patients’ genetic profiles, pharmacists can now tailor medication choices, leading to more effective therapies and fewer adverse reactions. Studies show that up to 30% of patients experience adverse drug reactions that could be avoided with pharmacogenomic testing. Pharmacogenomics has been shown to improve medication efficacy by 25-30%, optimizing treatment plans for better patient outcomes. As pharmacists, embracing this science enables us to go beyond the one-size-fits-all approach and offer truly personalized care. How are you incorporating pharmacogenomics into your practice? #Pharmacogenomics #PersonalizedMedicine #PharmacyInnovation #PrecisionMedicine #BetterOutcomes

#DYK about 16 million Americans experience gastroparesis symptoms, and the majority go untreated as there is no chronic treatment option?     CinDome Pharma is enrolling the #envision3d clinical trial to investigate deudomperidone (CIN-102) as a potential, chronic therapy for gastroparesis and fill this unmet medical need. Learn more about our work at: cindome.com and www.gastroparesistrial.com #GastroparesisAwarenessMonth #GastroparesisAwareness #LivingWithGP 

In case you missed it, you can watch our BioIndustry Association (BIA) and RNID webinar discussing clinical trials of hearing therapeutics and sharing learnings relevant to those working in other novel therapeutic areas. 👇 #clinicaltrials #hearingloss

A recent consensus from an international task force highlights the urgent need for clinical trials focusing on alcohol use and its impact on liver disease. The expert recommendations, published by UT Southwestern Medical Center in Nature, stress the importance of addressing the stigma associated with alcohol use disorder (AUD) and alcohol-related liver disease (ALD). These insights align with Adial Pharmaceuticals (NASDAQ: ADIL) and their commitment to developing innovative treatments for AUD, reinforcing the need for collaborative and stigma-free research efforts. For more: https://bit.ly/3zB0Pd4 #AUD #ClinicalTrials #HealthcareInnovation #HealthResearch

🧠 SetPoint Medical reports positive results from neuroimmune modulation device study SetPoint System is a neuroimmune modulation device that showed a clinical benefit in adults living with moderate-to-severe rheumatoid arthritis (RA). RESET-RA is a two-staged, multicentre, randomised, sham-controlled, double-blind clinical trial that enrolled a total of 242 patients across 41 sites in the US. The study evaluated the system as a potential neuroimmune modulation treatment for RA patients who are intolerant to disease-modifying anti-rheumatic drugs (DMARDs). Read more online: https://lnkd.in/eErbvxEM 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

We are evaluating the effectiveness of our investigational oral therapy for #ThyroidEyeDisease (TED) in a Phase 2b/3 clinical trial. Learn more about LIDS: https://lnkd.in/e4xE8anj

Sanofi Presents Results from the P-II Study of Frexalimab for the Treatment of Multiple Sclerosis #sanofi #frexalimab #multiplesclerosis #clinicaltrial #phase2 #plasmanfllevels #safety #efficacy

Innovation in new drug treatments for neurological diseases is thriving, with no signs of slowing down. How drugs are priced in the US drug distribution chain can help demystify the opaque process of drug pricing. In this latest issue of Continuum, we provide a guide for neurologists about drug pricing in the US. Follow along for this handy cheat sheet and the accompanying interview! https://lnkd.in/ggjWZuT6

Developing advanced sustained-release dosage forms ensures consistent therapeutic effects, enhanced patient compliance, and optimized drug delivery. These systems are especially impactful in managing chronic conditions like cardiovascular diseases, where controlled, precise drug release can improve outcomes and quality of life. SmaBio Labs leverages cutting-edge formulation techniques and innovative release mechanisms to design solutions tailored to your molecule's unique properties. From concept to commercialization, we ensure efficiency and precision at every stage of development. Curious about the science behind sustained-release formulations and their role in cardiovascular therapies? Visit smabiolabs.com to explore the details. #SustainedRelease #DrugDelivery #CDMO #Innovation #SmaBioLabs #cardiovascularmedication